Strategy for the development of novel anticancer drugs

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 52, Issue 1, 2003, Pages

  Saijo, Nagahiro ^a   Tamura, Tomohide ^a   Nishio, Kazuto ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Clinical trial; Target based drug; Translational study

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 7 HYDROXYSTAUROSPORINE; ANGIOGENESIS INHIBITOR; CD20 ANTIGEN; CETUXIMAB; CMA 672; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVOPIRIDOL; GEFITINIB; IMATINIB; INDISULAM; MATRIX METALLOPROTEINASE INHIBITOR; MCC 465; MELANOMA ANTIGEN; N ACETYLCOLCHINOL PHOSPHATE; PROSTATE ANTIGEN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE C; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SEMAXINIB; TAK 165; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN;

CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; HUMAN; JAPAN; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS;

EID: 0041323345     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Birmingham K (2002) What is translational research? Nat Med 8:647
2. Bissett D, von Pawel J, Mercier R, Price A, Nicolson M, Shepherd F, Mazabel E, Penning C, Zhang MH, Collier MA (2002) Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol Abstract 1183
3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235
4. Cunningham D, de Gramont A, Schiethauer W, Smakal M, Humblet Y, Kurteva G, Iveson T, Andre T, Dostalova J, Illes A, Jia X, Palmer P (2002) Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra™) in advanced refractory colorectal cancer. Proc Am Soc Clin Oncol Abstract 502
5. Druker BJ (2002) STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study. Proc Am Soc Clin Oncol Abstract 1
6. Fielding J, Scholefield J, Stuart R, Hawkins R, McCulloch P, Maughan T, Seymour M, Van Cutsem E, Thorlacius-Ussing O, Hovendal C (2000) A randomized double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc Am Soc Clin Oncol Abstract 929
7. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki Y, Vansteenkiste JF, Kudo S, Averbuch S, Macleod A, Feyereislova A, Baselga J (2002) Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol Abstract 1188
8. Gardner SN, Feranandes M (2003) The redemption of Sisyphus: clinical anticancer drug development of the single gate initiative. Lancet Oncol (personal communication)
9. Gatzemeier U, Groth G, Hirsh V, Butts CA, Van Zandwijk N, Shepherd F, Langer B, Rosso R (2002) Gemcitabine/cisplatin alone and with trastuzumab (Herceptin) in patients with non-small cell lung cancer (NSCLC) expressing HER2: results of a randomized phase II study. Proc Am Soc Clin Oncol Abstract 1185
10. Giaccone G, Johnson DH, Manegold C, Caggliotti GV, Rosell R, Wolf M, Rennie P, Ochs J, Averbush S, Fandi A (2002) A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). Ann Oncol [Suppl] 13:2
11. Hirte HW, Vergote IB, Jeffrey JR, Grimshaw RN, Stuart GC, Mendiola C, Vorobiof DA, Carey MS, Coppieters S, Schwartz B, Tu D, Sadura A, Seymour L (2001) An international multicentre phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/paclitaxel + platinum-containing chemotherapy (CT). Proc Am Soc Clin Oncol Abstract 843
12. Johnson DH, Herbst R, Giaccone G, Schiller J, Natale RB, Miller V, Wolf M, Helton A, Averbush S, Grows J (2002) ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 13 [Suppl 5]:127
13. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis C, Albain KS, Brahmer JR, Sandler A, Crawford J, Lutzker SG, Lilenbaum R, Helms L, Wolf M, Averbuch S, Ochs J, Kay A (2002) A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol Abstract 1166
14. Moore M, Hamm J, Eisenberg P, Dagenais M, Hagan K, Fields A, Greenberg B, Schwartz B, Ottaway J, Zee B, Seymour L (2000) A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY 12-9566 (9566) in patients (PTS) with advanced pancreatic cancer. Proc Am Soc Clin Oncol Abstract 930
15. Saijo N (2002) The molecular biology and signal transduction of epidermal growth factor receptor. New Dev Lung Cancer 1:2
16. Saijo N (2002) Translational study in cancer research. Intern Med 41:770
17. Saijo N, Tamura T, Nishio K (2000) Problems in the development of target-based drugs. Cancer Chemother Pharmacol [Suppl] 46:S43
18. Saijo N, Tamura T, Yamamoto N, Nishio K (2001) New strategies for cancer therapy in the 21st century. Cancer Chemother Pharmacol 48 [Suppl 1]:S102
19. Shepherd FA, Giaccone G, Debruyne C, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Zee B, Sadura A, Seymour L (2001) Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first line chemotherapy: an NCIC-CTG and EORTC study. Proc Am Soc Clin Oncol Abstract 11
20. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783
21. Smylie M, Mercier R, Aboulafia D, Tucker R, Bonomi P, Collier M, Keller MR, Stuart-Smith J, Knowles M, Clendeninn NJ, Shepherd F (2001) Phase III study of the matrix metalloprotease inhibitor (MMP) prinomastat in patients having advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol Abstract 1226
22. Van Cutsem E, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Neumann H, Safran H, Humblet Y, van de Velde H, Ma Y, Von Hoff D (2002) Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer. Proc Am Soc Clin Oncol Abstract 517